Moreover, among the 225 patients who received standard chemotherapy, those with higher MN1 expression (≥ median) as well as ASXL1 mutation had shorter overall survival compared to those with higher MN1 expression but without ASXL1 mutation (Fig. 6b), suggesting a possible cooperative effect between these two genetic aberrancies in AML patients. The gene discussed is ASXL1; the disease is acute myeloid leukemia.